Elite Pharmaceuticals (OTCMKTS:ELTP) Share Price Crosses Below 200-Day Moving Average - What's Next?

Key Points

• Shares fell below the 200-day moving average, trading as low as $0.3705 and last at $0.3765 on volume of 188,371 shares versus a 200-day MA of $0.53.
• Recent quarter showed EPS of $0.01 on $31.59 million revenue with a net margin of 30.98% and ROE of 47.93%, while the stock carries a market cap of $405.53 million and a P/E of 12.55.
• Elite is a Houston-based specialty pharmaceutical firm focused on complex dosage forms and oncology/injectables, and it reports a strong balance sheet with a current ratio of 7.34, quick ratio of 5.44 and debt-to-equity of 0.05.

Elite Pharmaceuticals Inc. (OTCMKTS:ELTP - Get Free Report)'s share price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.53 and traded as low as $0.3705. Elite Pharmaceuticals shares last traded at $0.3765, with a volume of 188,371 shares traded.

Elite Pharmaceuticals Stock Performance

The company has a current ratio of 7.34, a quick ratio of 5.44 and a debt-to-equity ratio of 0.05. The stock's 50 day moving average is $0.42 and its 200 day moving average is $0.53. The stock has a market capitalization of $405.53 million, a price-to-earnings ratio of 12.55 and a beta of 0.35.

Elite Pharmaceuticals (OTCMKTS:ELTP - Get Free Report) last announced its earnings results on Tuesday, February 17th. The specialty pharmaceutical company reported $0.01 earnings per share (EPS) for the quarter. Elite Pharmaceuticals had a net margin of 30.98% and a return on equity of 47.93%. The company had revenue of $31.59 million during the quarter.

Elite Pharmaceuticals Company Profile

Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.

Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.